Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Loses Oversight Of Yaz DTC Ads Under Agreement With States Attorneys General

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA has oversight over DTC advertising for Bayer’s Yaz contraceptive after the company violated an earlier agreement with state attorneys general.
Advertisement

Related Content

DTC Held Hostage? FDA Pre-Review of TV Ads May Delay Rx Campaigns
Bayer Tries Google Format To Keep Yaz Name In Sponsored Link And Meet Risk Requirements
Bayer Tries Google Format To Keep Yaz Name In Sponsored Link And Meet Risk Requirements
FDA Warns King Of Warning Letter: Firm Got Head Start On Fixing Embeda Ads
Allergan Under Investigation By Oregon For Deceptive Promotions
Inflamed Language: FDA Sends Harsh Warning Letter To Allergan For Acne Drug
Product Refinements Can Bring Product Liability: Bayer's Yaz And Yasmin Hit With Wave of Personal Injury Suits
FDA Ad Enforcement Steams On; Are “Days Of Pushing The Envelope” Over?
Yaz ad gets FDA-OK make-over
Advertising Citations Reach Record High: Another Way To Regulate Pharma?

Topics

Advertisement
UsernamePublicRestriction

Register

PS068967

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel